Alzheimer’s disease (AD): protective factors
Evidence-based neurology checklist on alzheimer’s disease (ad): protective factors: Genetic KLOTHO VS (KL-VS): this mitigates APOE4-associated Aβ aggregation Lifestyle Drug-related protective factors Nutritional protective factors Other potential protective factors
Genetic
- KLOTHO VS (KL-VS): this mitigates APOE4-associated Aβ aggregation
Lifestyle
Drug-related protective factors
Nutritional protective factors
Other potential protective factors
References
- Xu W, Tan L, Wang HF, et al. Meta-analysis of modifiable risk factors for Alzheimer's disease. JNNP 2015; 86:1299-1306.
- Lindsay J, Laurin D, Verreault R, et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian study of health and aging. Am J Epidemiol 2002; 156:445-453.
- Erickson CM, Schultz SA, Oh JM, et al.KLOTHO heterozygosity attenuates APOE4-related amyloid burden in preclinical AD. Neurology 2019; 92:e1878-e1889.
- Sewell KR, Solis-Urra P, Huang H, et al. Cognitive and brain reserve as modifiers of early Alzheimer disease-related cognitive vulnerability. Neurology 2026; 106:e214833.
- Chen H, Wang J, Lai S, et al. Smoking cessation, weight change, and risk of dementia: a prospective cohort study. Neurology 2026; 106:e218123.
- And 9 more. Subscribe to see the full list
Related checklists
- Alzheimer’s disease (AD): risk factors
- Alzheimer’s disease (AD): clinical features
- Alzheimer's Disease (AD) v frontotemporal dementia (FTD)
- Alzheimer’s disease (AD): investigations
- Alzheimer’s disease (AD): emerging investigations
- Alzheimer’s disease (AD): preventative measures
- Alzheimer’s disease (AD): non-drug management
- Alzheimer’s disease (AD): conventional drug treatments
- Alzheimer’s disease (AD): lecanemab treatment
- Alzheimer’s disease (AD): investigational treatments
- Alzheimer’s disease: driving and safety issues